Oral Anti Diabetic Agents in the Hospital

Description

This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).

Conditions

Diabetes Mellitus

Talk to us

Study Overview

On this page

Study Details

Study overview

This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).

Use of Oral Antidiabetic Agents in Hospitalized Patients With Diabetes

Oral Anti Diabetic Agents in the Hospital

Condition
Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital Midtown, Atlanta, Georgia, United States, 30322

Atlanta

Emory University Hospital, Atlanta, Georgia, United States, 30322

Atlanta

Grady Memorial Hospital, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males or females, age 18-80 years admitted to a general medicine and surgery services
  • * Known history of T2D receiving OADs either as monotherapy or in combination therapy
  • * Admission BG \< 250 mg/dl or randomization BG \<250 mg/dl and not receiving basal insulin
  • * Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c \<7.5% within the past three months
  • * HbA1c \<10%
  • * No known history of diabetes
  • * Laboratory evidence of diabetic ketoacidosis
  • * Subjects with a history of type 1 diabetes (suggested by BMI \< 25 requiring insulin therapy or with a history of diabetic ketoacidosis, or ketonuria)
  • * Meeting any exclusion criteria based on specific contraindications to their home oral therapy
  • * Acute critical illness or cardiac surgery expected to require admission to a critical care unit
  • * Gastrointestinal obstruction, adynamic ileus, or expected to require gastrointestinal suction
  • * Medical or surgical patients expected to be kept NPO for \>24-48 hours after admission or after completion of surgical procedure
  • * Impaired renal function (eGFR \<30 ml/min)
  • * Current treatment with oral or injectable corticosteroid
  • * Mental condition rendering the subject unable to understand the nature and scope of the study
  • * Female subjects who are pregnant or breastfeeding at time of enrollment in the study
  • * New or recent onset (within two weeks) of coronavirus disease 2019 (COVID-19) infection at the time of admission

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Maya Fayfman, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2024-12-01